EM Imaging was founded in 2014 by an experienced team of scientists & clinicians. Together they have raised over £15 Million in non-dilutive funding from the Wellcome Trust, EPSRC and MRC to develop a unique range of SMART Agents that enable real-time molecular imaging for the diagnosis of a variety of disease states.
The EM Imaging team has decades of documented success in imaging agent discovery and development with expertise spanning medicinal chemistry, biochemistry and cell biology, along with direct clinical expertise. The team also has significant expertise in the clinical development, approval and reimbursement of molecular imaging agents.
EM Imaging plans to become a leader in offering targeted fluorescent optical imaging agents as a cost effective and accessible diagnostic modality. In doing so, EM Imaging’s core technology will address unmet needs in challenging diseases where mortality rates have not improved in the last 50 years. The company’s technology therefore offers the potential to drive a paradigm shift in the in-vivo diagnostic imaging market.